Compare Cenovus Energy Inc (CVE) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Quest Diagnostics Inc — how do they compare? Cenovus Energy Inc trades at $31.76 (market cap $57.90B), while Quest Diagnostics Inc trades at $230.82 (market cap $25.48B). The key difference: Cenovus Energy Inc is far larger — about 2.3× Quest Diagnostics Inc's market cap, and Cenovus Energy Inc pays the higher dividend (1.97%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Quest Diagnostics Inc for 56 Days on average.
| CVE | DGX | |
|---|---|---|
Market Cap | $57.90B | $25.48B |
Volume | 7,863,588 | 941,866 |
Sector | Energy | Health |
52-Week High | $33.92 | $247.45 |
52-Week Low | $15.85 | $173.49 |
Typical Hold Time | 46 Days | 56 Days |
Enterprise Value | $63.84B | $31.23B |
Dividend Yield | 1.97% | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.63, down 1.95% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong profitability with a 20.96% ROE and 11.48% net margin, supported by recent earnings beats. Cash flow trends indicate operational strength, though net cash flow was negative $353 million in 2025. Analyst sentiment is mixed with 40.74% buy ratings, while recent news highlights growth potential and value attributes.
Outlook: CVE offers value with a low P/E of 12.43 and solid earnings growth projections, but faces headwinds from volatile oil prices and mixed technical indicators. Risks include energy market fluctuations and debt levels, though institutional interest remains steady. The stock presents a balanced opportunity for value investors seeking energy exposure.
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
